Professionals 238 Users Online

Non-muscle Invasive Bladder Cancer Therapeutics Market

Market Study on Non-muscle Invasive Bladder Cancer Therapeutics: Chemotherapy Drugs Account for Leading Market Share

Non-muscle Invasive Bladder Cancer Therapeutics Market Segmented By Drug Type (Immunotherapy, Chemotherapy and Targeted Therapy)

Non-muscle Invasive Bladder Cancer Therapeutics Market Outlook (2023 to 2033)

The global non-muscle invasive bladder cancer therapeutics market expanded at a CAGR of 20.4% over the last 10 years and reached a valuation of US$ 2.2 billion in 2022. The market is forecasted to progress at a CAGR of 14.8% to reach US$ 9.8 billion by the end of 2033.

  • As assessed by Persistence Market Research, low-grade bladder cancer accounted for a market share of 69.8% in 2022.
  • Revenue from non-muscle invasive bladder cancer therapeutics reached 70.7% of the global bladder cancer therapeutics market size in 2022.

Methods used to treat non-muscle invasive bladder cancer that has not yet spread to the muscles of the bladder include a variety of pharmaceuticals, medications, and therapies. Several treatments are specifically designed to address this type of cancer, which has a more favorable prognosis than muscle-invasive bladder cancer, owing to its lower level of advancement. Immunotherapy, chemotherapy, radiation therapy, and surgery are among the treatments that are offered in the non-muscle invasive bladder cancer therapeutics market.

Development of medical technology and research over the past few years has contributed to the continuous rise of the non-muscle invasive bladder cancer treatment market. Individuals with non-muscle invasive bladder cancer had few treatment options, but today they have access to a wide range of therapies that can help them manage their illness. One of the most important advancements in this field is the use of gene therapy, targeted treatments, and immunotherapy to treat bladder cancer.

The industry has a bright future because of anticipated improvements in non-muscle invasive bladder cancer therapies due to increased research and development spending. Immune checkpoint inhibitors, tailored treatments, and intravesical treatments are only a few of the intriguing medications that are now being developed or tested in clinical studies. Early trials of these treatments have yielded encouraging results, and in the years to come, it is anticipated that they will dramatically improve patient outcomes for those with non-muscle invasive bladder cancer.

Over the forecast period, demand for non-muscle invasive bladder cancer therapies is anticipated to expand at a steady rate. The market is expected to expand as a result of factors, such as the increasing prevalence of bladder cancer, the rising desire for minimally invasive procedures, and a pipeline of novel medicines.

Report Attributes

Details

Non-muscle Invasive Bladder Cancer Therapeutics Market Size (2023)

US$ 2.5 Billion

Projected Market Value (2033)

US$ 9.8 Billion

Global Market Growth Rate (2023 to 2033)

14.8% CAGR

Market Share of Top 5 Countries

66.5%

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

What are the Factors Contributing to High Demand for Non-Muscle Invasive Bladder Cancer Therapies?

Increasing Prevalence of Bladder Cancer and Growing Demand for Minimally Invasive Techniques

As a result of increased financing for cancer research, the quality of life for cancer patients has improved significantly and patient survival rates have significantly increased.

The National Cancer Institute (NCI) offers funding for research projects in fields where the commercial sector lacks interest, including ground-breaking research and projects on cancer screening, prevention, and rare malignancies.

  • The National Cancer Institute (NCI) received US$ 6.9 billion in compliance with the United State government’s Consolidated Appropriations Act of 2022, a net increase of US$ 353 million from FY 2021. The National Cancer Institute (NCI) received US$ 5.2 billion from the U.S. government in April 2016, a 5.3% increase from the previous year.

Usage of expedited approval procedures for the development of anti-cancer medications has greatly expanded in recent years due to the benefits of the treatment’s high efficiency and cost-effectiveness. Increasing prevalence of bladder cancer, particularly in the senior population, and the growing demand for minimally invasive surgical techniques are significant market drivers.

The availability of efficient treatment alternatives, such as immunotherapy and chemotherapy, as well as the development of technology used for the detection and treatment of bladder cancer, which is improving patient outcomes, are additional factors influencing market expansion. More people are becoming aware of bladder cancer and the importance of early cancer detection, which is likely to contribute to market expansion in the years to come.

Rising incidence of bladder cancer, especially in elderly people, is also a significant contributing cause. The need for bladder cancer treatments has increased as a result of improved cancer diagnostic and therapy options brought on by advancements in medical technology. Research and development initiatives are revealing fresh, more efficient treatment choices that could propel this market's expansion. It is anticipated that growing investments by industry leaders will spur innovation and encourage the development of non-muscle invasive bladder cancer therapies.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

What are the Hindrances to the Adoption of Non-Muscle Invasive Bladder Cancer Therapies?

“High Treatment Cost and Unfavorable Side Effects of Some Medications”

Growth of this market is restricted by a lack of understanding of the ailment and its treatment, high costs associated with care, and unfavorable side effects of some medications. The fact that several important cancer medications are not available in underdeveloped and emerging nations is one of the main issues restricting the growth of the market for pharmaceuticals to treat bladder cancer.

The strong probability of bladder cancer recurrence, which needs continuing therapy and surveillance, is also one of the significant challenges. With numerous viable treatment choices, there is also a lot of competition in the market. There is a growing interest in alternative medicines as a result of worries about the potential negative effects of various treatments.

Demand for novel, more focused therapies that can increase the effectiveness and safety of this treatment is also on the rise. The necessity for continued research and development in the area of non-muscle-invasive bladder cancer therapies is generally highlighted by these difficulties. Other barriers to getting access to and using cancer treatments include their high cost, limited coverage under public insurance systems, exclusion from the EML, and limited or no availability of drugs in institutions.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Country-wise Insights

Why is the United States a Lucrative Market for Providers of Non-Muscle Invasive Bladder Cancer Therapies?

“Favorable Reimbursement Policies and Advanced Treatment Methods”

The United States accounted for 43% share of the global market in 2022.

Demand for non-muscle invasive bladder cancer therapies in the United States is anticipated to rise significantly owing to technologically advanced diagnostic and therapeutic methods and advantageous reimbursement practices.

Rise in bladder cancer cases, improvements in medical technology, and rising interest in minimally invasive procedures have all contributed to the market's expansion. Several of the nation's pharmaceutical businesses are concentrating on the development of novel medications and treatments to enhance patient outcomes.

What is the Demand Outlook for Non-Muscle Invasive Bladder Cancer Therapies in China?

“Government Policies Supporting Advanced Healthcare”

China accounted for 9.2% share of the global market in 2022.

One of the key factors for the rising demand for non-muscle invasive bladder cancer therapies, along with China's aging population and rising healthcare costs, is the rising incidence of bladder cancer in the country. The market is expanding as a result of improvements in medical technology as well as rising public knowledge of the existence of non-muscle invasive bladder cancer therapies.

Demand for non-muscle invasive bladder cancer therapies is anticipated to increase as a result of the government's supportive policies and activities boosting the development of the healthcare industry in China. The increased accessibility of cutting-edge treatments and products brought about by the entry of international pharmaceutical corporations into the Chinese market has improved the outlook for patients with non-muscle-invasive bladder cancer.

How is the Demand for Non-Muscle Invasive Bladder Cancer Therapies Shaping Up in Germany?

“Increasing Awareness about Early Cancer Diagnosis”

Germany held 5.8% share of the global market in 2022.

Due to the rising incidence of bladder cancer and the demand for efficient therapies, the non-muscle invasive bladder cancer therapeutics market in Germany is expanding. The market is anticipated to expand significantly over the upcoming years as a result of growing public awareness of the importance of early cancer detection and treatment.

Rising acceptance of less invasive techniques, growing awareness of early diagnosis and treatment, and increased research and development efforts in the field are other factors fueling market expansion.

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Category-wise Insights

Which Grade-based Non-Muscle Invasive Bladder Cancer Accounts for Higher Revenue Generation?

“Rapidly Increasing Incidence of Low-grade Bladder Cancer”

The low-grade bladder cancer segment held 69.8% market share in 2022.

Demand for non-muscle invasive bladder cancer therapies has grown substantially as a result of the high incidence rate of low-grade bladder cancer. Low-grade bladder cancer is one of the most prevalent kinds of bladder cancer and, if untreated, frequently develops into high-grade bladder cancer. Early detection and treatment of low-grade bladder cancer are given more importance to stop its progression.

Because of this, there is now a greater need for non-muscle invasive bladder cancer treatments, which are intended to treat low-grade, early-stage bladder cancer without invasive surgical procedures.

Which Drug Type is Extensively Used in the Treatment of Non-muscle-invasive Bladder Cancer?

“Wide Adoption of Chemotherapy in Treating Bladder Cancer Due to Its High Effectiveness and Improved Patient Outcomes”

The chemotherapy drug segment held 45.2% of the market in 2022.

Chemotherapy has been a crucial part of the management of bladder cancer that is non-muscle invasive, and its wide usage has fueled the expansion of the therapies industry. To help shrink tumors and improve patient outcomes, chemotherapy is frequently used in combination with other treatments, such as surgery and radiation therapy.

The creation of more potent chemotherapy medications has also contributed to the market's continued expansion. More cutting-edge treatment options are anticipated to emerge in the years to come, as research into the underlying biology of non-muscle-invasive bladder cancer continues to yield new insights.

Competition Landscape

The non-muscle invasive bladder cancer therapeutics market is highly competitive, with companies striving to expand their reach in emerging markets and maintain their relationships with existing distributors. The competitive landscape includes an examination of several global and local companies that hold significant market shares, as well as strategies such as mergers and acquisitions and partnerships with key players.

  • AstraZeneca expanded its portfolio for treating hematological cancers by acquiring TeneoTwo and its clinical-stage T-cell engager in July 2022.
  • Cipla and Roche Products (India) Pvt. Ltd. signed a distribution agreement in June 2022 to expand the scope of their partnership to include the marketing and distribution of Roche's branded oncology drugs.

Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the non-muscle invasive bladder cancer therapeutics market, which are available in the full report.

Non-muscle Invasive Bladder Cancer Therapeutics Industry Report Scope

Attribute

Details

Forecast Period

2023 to 2033

Historical Data Available for

2012 to 2022

Market Analysis

US$ Billion for Value

Key Countries Covered

  • United States
  • Canada
  • Brazil
  • Argentina
  • Mexico
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Benelux
  • India
  • Thailand
  • Malaysia
  • Indonesia
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Türkiye
  • GCC Countries
  • North African Countries
  • South Africa

Key Market Segments Covered

  • Cancer Grade
  • Drug Type
  • Distribution Channel
  • Region

Key Companies Covered

  • Pfizer Inc.
  • Merck KGaA
  • Merck & Co.
  • AstraZeneca PLC
  • Roche Holding AG (Genentech)
  • Astellas Pharma Inc.
  • J&J (Janssen Biotech)
  • Cipla Inc.
  • Amneal Pharma
  • Bristol Myers Squibb Co.
  • Dr. Reddy’s Laboratories, Inc.
  • Gilead Sciences Inc.
  • Endo Pharma
  • UroGen Pharma, Inc.
  • Teva Pharmaceuticals (Actavis)
  • Hikma Pharmaceuticals
  • Incytes

Report Coverage

  • Market Forecast
  • Competition Intelligence
  • DROT Analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Key Segments of Non-muscle Invasive Bladder Cancer Therapeutics Industry

Cancer Grade:

  • Low-grade Bladder Cancer
  • High-grade Bladder Cancer

Drug Type:

  • Immunotherapy
    • Bacillus Calmette-Guerin
    • Avelumab
    • Nivolumab
    • Pembrolizumab
    • Others
  • Chemotherapy
    • Mitomycin C
    • Docetaxel
    • Paclitaxel
    • Cisplatin
    • Others
  • Targeted Therapy
    • Erdafitinib
    • Enfortumab Vedotin-ejfv
    • Sacituzumab Govitecan
    • Others

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Specialty Pharmacies
  • Online Pharmacies

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

- Companies Covered in This Report -

  • Pfizer Inc.
  • Merck KGaA
  • AstraZeneca PLC
  • Roche Holding AG (Genentech)
  • Astellas Pharma Inc.
  • J&J (Janssen Biotech)
  • Cipla Inc.
  • Amneal Pharma
  • Bristol Myers Squibb Co.
  • Dr. Reddy’s Laboratories, Inc.
  • Gilead Sciences Inc.
  • Endo Pharma
  • UroGen Pharma, Inc.
  • Teva Pharmaceuticals (Actavis)
  • Hikma Pharmaceuticals
  • Incyte

- Frequently Asked Questions -

The global non-muscle invasive bladder cancer therapeutics market was valued at US$ 2.2 billion in 2022.

The market for non-muscle invasive bladder cancer treatment is valued at US$ 2.5 billion in 2023.

Revenue from non-muscle invasive bladder cancer treatments is set to reach US$ 9.8 billion by 2033.

Sales of non-muscle invasive bladder cancer therapeutics are set to rise at a CAGR of 14.8% through 2033.

The U.S., China, Germany, the U.K., and Japan collectively account for 66.5% market share.

The United States accounted for 43% market share in 2022.

China accounted for 9.2% share of the global market in 2022.

Germany held 5.8% of the global market in 2022.

Chemotherapy drugs held 45.2% share of the global market in 2022.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate